World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
49854
World Ranking
10265
National Ranking
989

Overview

Nicholas C. Turner is affiliated with the Royal Marsden NHS Foundation Trust in the United Kingdom. Their research contributions focus primarily on oncology and related biomedical fields, with an emphasis on breast cancer and molecular biology.

Their notable recent papers include:

  • Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer, 2023, New England Journal of Medicine
  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, 2021, Annals of Oncology
  • ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group, 2022, Annals of Oncology
  • Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial, 2021, The Lancet Oncology
  • Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future, 2020, The Lancet

Their frequent co-authors reflect collaborative research efforts and include:

  • Komal Jhaveri
  • Alicia Okines
  • Mafalda Oliveira
  • Hope S. Rugo
  • Alistair Ring

Nicholas C. Turner has published extensively in several scientific journals, with the most frequent venues being:

  • Cancer Research (67 publications)
  • Journal of Clinical Oncology (35 publications)
  • Annals of Oncology (27 publications)
  • Clinical Cancer Research (26 publications)
  • ESMO Open (10 publications)

The main fields of study they contribute to are:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broad fields, major subfields of interest include:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Genetics
  • Molecular Biology

The primary topics of their work focus on:

  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics
  • Breast Cancer Treatment Studies
  • PARP inhibition in cancer therapy
  • Cancer-related Molecular Pathways

Best Publications

  • Fibroblast growth factor signalling: from development to cancer

    Nicholas Turner;Richard Grose

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • Hallmarks of 'BRCAness' in sporadic cancers

    Nicholas Turner;Andrew Tutt;Alan Ashworth

  • Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi

  • The history and future of targeting cyclin-dependent kinases in cancer therapy

    Uzma Asghar;Agnieszka K. Witkiewicz;Nicholas C. Turner;Erik S. Knudsen

  • Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

    Jason D. Merker;Geoffrey R. Oxnard;Carolyn Compton;Maximilian Diehn

  • Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

    Nuala McCabe;Nicholas C. Turner;Christopher J. Lord;Katarzyna Kluzek

  • Mutation Tracking in Circulating Tumor DNA Predicts Relapse in Early Breast Cancer

    Isaac Garcia-Murillas;Gaia Schiavon;Gaia Schiavon;Britta Weigelt;Charlotte Ng

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Treating cancer with selective CDK4/6 inhibitors

    Ben O'Leary;Richard S. Finn;Nicholas C. Turner;Nicholas C. Turner

  • FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

    Nicholas Turner;Alex Pearson;Rachel Sharpe;Maryou Lambros

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    A. Gennari;F. André;C.H. Barrios;J. Cortés

  • BRCA1 dysfunction in sporadic basal-like breast cancer.

    NC Turner;JS Reis-Filho;JS Reis-Filho;AM Russell;RJ Springall

  • Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

    Charlotte Fribbens;Ben O’Leary;Lucy Kilburn;Sarah Hrebien

  • Advances and challenges in targeting FGFR signalling in cancer

    Irina S. Babina;Nicholas C. Turner;Nicholas C. Turner

  • Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.

    Maria Teresa Herrera-Abreu;Marta Palafox;Uzma Asghar;Martín A Rivas

  • Basal-like breast cancer and the BRCA1 phenotype.

    N C Turner;J S Reis-Filho

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

    H J Burstein;G Curigliano;B Thürlimann;W P Weber

  • Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

    Gaia Schiavon;Gaia Schiavon;Sarah Hrebien;Isaac Garcia-Murillas;Rosalind J. Cutts

  • The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

    Ben O'Leary;Ben O'Leary;Rosalind J. Cutts;Yuan Liu;Sarah Hrebien

Frequent Co-Authors

Massimo Cristofanilli
Massimo Cristofanilli Cornell University
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Mitch Dowsett
Mitch Dowsett Breast Cancer Research Foundation
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Alan Ashworth
Alan Ashworth University of California, San Francisco
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Jorge S. Reis-Filho
Jorge S. Reis-Filho Memorial Sloan Kettering Cancer Center
Judith M. Bliss
Judith M. Bliss Institute of Cancer Research
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Sibylle Loibl
Sibylle Loibl Goethe University Frankfurt

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As the healthcare field expands, students interested in Medicine in the USA are exploring alternative and complementary career pathways through flexible online programs. Options such as a nutrition degree online offer an excellent route for those passionate about diet, wellness, and disease prevention. Graduates can pursue careers in clinical nutrition, public education, and wellness coaching.

For those aiming for leadership, enrolling in one of the best online mha programs can open doors to management roles in hospitals and healthcare systems. If you’re already a registered nurse, online rn to bsn programs without clinical requirements make it easier to advance your qualifications and career prospects without stepping away from work.

For nurses seeking the highest clinical expertise, dnp online programs provide an efficient pathway to leadership in advanced practice nursing. These programs are ideal for those wanting to influence patient care at a systemic level or move into education and research.

Best Scientists Citing Nicholas C. Turner

Trending Scientists